Loading…

Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model

Long COVID has become a significant global health and economic burden, yet there are currently no established methods or diagnostic tools to identify which patients might benefit from specific treatments. One of the major pathophysiological factors contributing to Long COVID is the presence of hyper...

Full description

Saved in:
Bibliographic Details
Published in:Heliyon 2023-09, Vol.9 (9), p.e19605-e19605, Article e19605
Main Authors: Turner, Simone, Laubscher, Gert Jacobus, Khan, M Asad, Kell, Douglas B., Pretorius, Etheresia
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c511t-57ebd429a1e09e9cea1180d53bbdeba0f1d4b90e6b927ddc2d850907200470bc3
cites cdi_FETCH-LOGICAL-c511t-57ebd429a1e09e9cea1180d53bbdeba0f1d4b90e6b927ddc2d850907200470bc3
container_end_page e19605
container_issue 9
container_start_page e19605
container_title Heliyon
container_volume 9
creator Turner, Simone
Laubscher, Gert Jacobus
Khan, M Asad
Kell, Douglas B.
Pretorius, Etheresia
description Long COVID has become a significant global health and economic burden, yet there are currently no established methods or diagnostic tools to identify which patients might benefit from specific treatments. One of the major pathophysiological factors contributing to Long COVID is the presence of hypercoagulability; this results in insoluble amyloid microclots that are resistant to fibrinolysis. Our previous research using fluorescence microscopy has demonstrated a significant amyloid microclot load in Long COVID patients. However, this approach lacked the elements of statistical robustness, objectivity, and rapid throughput. In the current study, we have used imaging flow cytometry for the first time to show a significantly increased concentration and size of these microclots. We identified notable variations in size and fluorescence between microclots in Long COVID and those of controls even using a 20× objective. By combining cell imaging and the high-event-rate and full-sample analysis nature of a conventional flow cytometer, imaging flow cytometry can eliminate erroneous results and increase accuracy in gating and analysis beyond what pure quantitative measurements from conventional flow cytometry can provide. Although imaging flow cytometry was used in our study, our results suggest that the signals indicating the presence of microclots should be easily detectable using a conventional flow cytometer. Flow cytometry is a more widely available technique than fluorescence microscopy and has been used in pathology laboratories for decades, rendering it a potentially more suitable and accessible method for detecting microclots in individuals suffering from Long COVID or conditions with similar pathology, such as myalgic encephalomyelitis. •Imaging flow cytometry utilizing a novel rapid flow cytometric detection method is a promising method for detecting amyloid fibrin(ogen) microclots in conditions associated with clotting pathology.•While this investigation represents a preliminary study, it lays the foundation for further research into the method's utility as a diagnostic tool for individuals with Long COVID.•Though challenging, future research can explore potential correlations between microclot detection and specific Long COVID symptoms and comorbidities, enhancing our understanding of the pathophysiology and tools to detect this condition.•The method's ability to evaluate amyloid microclot presence, concentration, and size offers valuable insights for c
doi_str_mv 10.1016/j.heliyon.2023.e19605
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_038e1f97211846c48658f0f14aadf1d0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405844023068135</els_id><doaj_id>oai_doaj_org_article_038e1f97211846c48658f0f14aadf1d0</doaj_id><sourcerecordid>2874837865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-57ebd429a1e09e9cea1180d53bbdeba0f1d4b90e6b927ddc2d850907200470bc3</originalsourceid><addsrcrecordid>eNqFkk2P2yAQhq2qlbra7k-oxHF7SDpgsHEvVZR-RVppL22vCMM4IcKwBSeVb_3pJZuo7Z56YUbD8LwwvFX1msKSAm3e7pc79G6OYcmA1UukXQPiWXXFOIiF5Bye_5O_rG5y3gMAFbLp2vqq-rUyBj0mPbmwJdZlE4-Y5ndkRULJPBl8_EnMPMURp-QMKWEXLRliIhYnNI_nBtcnF27jFsMbosfZR2fJ6EyKxscpk0M-dflYlvX9980HojPRZIwW_avqxaB9xptLvK6-ffr4df1lcXf_ebNe3S2MoHRaiBZ7y1mnKUKHnUFNqQQr6r632GsYqOV9B9j0HWutNcxKAR20DIC30Jv6utqcuTbqvXpIbtRpVlE79ViIaat0mpzxqKCWSIeuZUWCN4bLRsihKHCtbdGBwnp_Zj0c-hGtwTAl7Z9An-4Et1PbeFQUhJCyZYVweyGk-OOAeVJjGT16rwPGQ1ZMtlzWbVEureLcWqaZc8Lhjw4FdbKA2quLBdTJAupsgb-XxDLVo8OksnEYDFqXyreVZ7v_EH4DCyW_uA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2874837865</pqid></control><display><type>article</type><title>Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model</title><source>ScienceDirect</source><source>Open Access: PubMed Central</source><creator>Turner, Simone ; Laubscher, Gert Jacobus ; Khan, M Asad ; Kell, Douglas B. ; Pretorius, Etheresia</creator><creatorcontrib>Turner, Simone ; Laubscher, Gert Jacobus ; Khan, M Asad ; Kell, Douglas B. ; Pretorius, Etheresia</creatorcontrib><description>Long COVID has become a significant global health and economic burden, yet there are currently no established methods or diagnostic tools to identify which patients might benefit from specific treatments. One of the major pathophysiological factors contributing to Long COVID is the presence of hypercoagulability; this results in insoluble amyloid microclots that are resistant to fibrinolysis. Our previous research using fluorescence microscopy has demonstrated a significant amyloid microclot load in Long COVID patients. However, this approach lacked the elements of statistical robustness, objectivity, and rapid throughput. In the current study, we have used imaging flow cytometry for the first time to show a significantly increased concentration and size of these microclots. We identified notable variations in size and fluorescence between microclots in Long COVID and those of controls even using a 20× objective. By combining cell imaging and the high-event-rate and full-sample analysis nature of a conventional flow cytometer, imaging flow cytometry can eliminate erroneous results and increase accuracy in gating and analysis beyond what pure quantitative measurements from conventional flow cytometry can provide. Although imaging flow cytometry was used in our study, our results suggest that the signals indicating the presence of microclots should be easily detectable using a conventional flow cytometer. Flow cytometry is a more widely available technique than fluorescence microscopy and has been used in pathology laboratories for decades, rendering it a potentially more suitable and accessible method for detecting microclots in individuals suffering from Long COVID or conditions with similar pathology, such as myalgic encephalomyelitis. •Imaging flow cytometry utilizing a novel rapid flow cytometric detection method is a promising method for detecting amyloid fibrin(ogen) microclots in conditions associated with clotting pathology.•While this investigation represents a preliminary study, it lays the foundation for further research into the method's utility as a diagnostic tool for individuals with Long COVID.•Though challenging, future research can explore potential correlations between microclot detection and specific Long COVID symptoms and comorbidities, enhancing our understanding of the pathophysiology and tools to detect this condition.•The method's ability to evaluate amyloid microclot presence, concentration, and size offers valuable insights for clinical applications.</description><identifier>ISSN: 2405-8440</identifier><identifier>EISSN: 2405-8440</identifier><identifier>DOI: 10.1016/j.heliyon.2023.e19605</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><subject>Amyloid microclots ; Fluorescence ; Imaging flow cytometry ; Long COVID</subject><ispartof>Heliyon, 2023-09, Vol.9 (9), p.e19605-e19605, Article e19605</ispartof><rights>2023 The Authors</rights><rights>2023 The Authors 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-57ebd429a1e09e9cea1180d53bbdeba0f1d4b90e6b927ddc2d850907200470bc3</citedby><cites>FETCH-LOGICAL-c511t-57ebd429a1e09e9cea1180d53bbdeba0f1d4b90e6b927ddc2d850907200470bc3</cites><orcidid>0000-0002-9108-2384</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558872/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2405844023068135$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids></links><search><creatorcontrib>Turner, Simone</creatorcontrib><creatorcontrib>Laubscher, Gert Jacobus</creatorcontrib><creatorcontrib>Khan, M Asad</creatorcontrib><creatorcontrib>Kell, Douglas B.</creatorcontrib><creatorcontrib>Pretorius, Etheresia</creatorcontrib><title>Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model</title><title>Heliyon</title><description>Long COVID has become a significant global health and economic burden, yet there are currently no established methods or diagnostic tools to identify which patients might benefit from specific treatments. One of the major pathophysiological factors contributing to Long COVID is the presence of hypercoagulability; this results in insoluble amyloid microclots that are resistant to fibrinolysis. Our previous research using fluorescence microscopy has demonstrated a significant amyloid microclot load in Long COVID patients. However, this approach lacked the elements of statistical robustness, objectivity, and rapid throughput. In the current study, we have used imaging flow cytometry for the first time to show a significantly increased concentration and size of these microclots. We identified notable variations in size and fluorescence between microclots in Long COVID and those of controls even using a 20× objective. By combining cell imaging and the high-event-rate and full-sample analysis nature of a conventional flow cytometer, imaging flow cytometry can eliminate erroneous results and increase accuracy in gating and analysis beyond what pure quantitative measurements from conventional flow cytometry can provide. Although imaging flow cytometry was used in our study, our results suggest that the signals indicating the presence of microclots should be easily detectable using a conventional flow cytometer. Flow cytometry is a more widely available technique than fluorescence microscopy and has been used in pathology laboratories for decades, rendering it a potentially more suitable and accessible method for detecting microclots in individuals suffering from Long COVID or conditions with similar pathology, such as myalgic encephalomyelitis. •Imaging flow cytometry utilizing a novel rapid flow cytometric detection method is a promising method for detecting amyloid fibrin(ogen) microclots in conditions associated with clotting pathology.•While this investigation represents a preliminary study, it lays the foundation for further research into the method's utility as a diagnostic tool for individuals with Long COVID.•Though challenging, future research can explore potential correlations between microclot detection and specific Long COVID symptoms and comorbidities, enhancing our understanding of the pathophysiology and tools to detect this condition.•The method's ability to evaluate amyloid microclot presence, concentration, and size offers valuable insights for clinical applications.</description><subject>Amyloid microclots</subject><subject>Fluorescence</subject><subject>Imaging flow cytometry</subject><subject>Long COVID</subject><issn>2405-8440</issn><issn>2405-8440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFkk2P2yAQhq2qlbra7k-oxHF7SDpgsHEvVZR-RVppL22vCMM4IcKwBSeVb_3pJZuo7Z56YUbD8LwwvFX1msKSAm3e7pc79G6OYcmA1UukXQPiWXXFOIiF5Bye_5O_rG5y3gMAFbLp2vqq-rUyBj0mPbmwJdZlE4-Y5ndkRULJPBl8_EnMPMURp-QMKWEXLRliIhYnNI_nBtcnF27jFsMbosfZR2fJ6EyKxscpk0M-dflYlvX9980HojPRZIwW_avqxaB9xptLvK6-ffr4df1lcXf_ebNe3S2MoHRaiBZ7y1mnKUKHnUFNqQQr6r632GsYqOV9B9j0HWutNcxKAR20DIC30Jv6utqcuTbqvXpIbtRpVlE79ViIaat0mpzxqKCWSIeuZUWCN4bLRsihKHCtbdGBwnp_Zj0c-hGtwTAl7Z9An-4Et1PbeFQUhJCyZYVweyGk-OOAeVJjGT16rwPGQ1ZMtlzWbVEureLcWqaZc8Lhjw4FdbKA2quLBdTJAupsgb-XxDLVo8OksnEYDFqXyreVZ7v_EH4DCyW_uA</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Turner, Simone</creator><creator>Laubscher, Gert Jacobus</creator><creator>Khan, M Asad</creator><creator>Kell, Douglas B.</creator><creator>Pretorius, Etheresia</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9108-2384</orcidid></search><sort><creationdate>20230901</creationdate><title>Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model</title><author>Turner, Simone ; Laubscher, Gert Jacobus ; Khan, M Asad ; Kell, Douglas B. ; Pretorius, Etheresia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-57ebd429a1e09e9cea1180d53bbdeba0f1d4b90e6b927ddc2d850907200470bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Amyloid microclots</topic><topic>Fluorescence</topic><topic>Imaging flow cytometry</topic><topic>Long COVID</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turner, Simone</creatorcontrib><creatorcontrib>Laubscher, Gert Jacobus</creatorcontrib><creatorcontrib>Khan, M Asad</creatorcontrib><creatorcontrib>Kell, Douglas B.</creatorcontrib><creatorcontrib>Pretorius, Etheresia</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Heliyon</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turner, Simone</au><au>Laubscher, Gert Jacobus</au><au>Khan, M Asad</au><au>Kell, Douglas B.</au><au>Pretorius, Etheresia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model</atitle><jtitle>Heliyon</jtitle><date>2023-09-01</date><risdate>2023</risdate><volume>9</volume><issue>9</issue><spage>e19605</spage><epage>e19605</epage><pages>e19605-e19605</pages><artnum>e19605</artnum><issn>2405-8440</issn><eissn>2405-8440</eissn><abstract>Long COVID has become a significant global health and economic burden, yet there are currently no established methods or diagnostic tools to identify which patients might benefit from specific treatments. One of the major pathophysiological factors contributing to Long COVID is the presence of hypercoagulability; this results in insoluble amyloid microclots that are resistant to fibrinolysis. Our previous research using fluorescence microscopy has demonstrated a significant amyloid microclot load in Long COVID patients. However, this approach lacked the elements of statistical robustness, objectivity, and rapid throughput. In the current study, we have used imaging flow cytometry for the first time to show a significantly increased concentration and size of these microclots. We identified notable variations in size and fluorescence between microclots in Long COVID and those of controls even using a 20× objective. By combining cell imaging and the high-event-rate and full-sample analysis nature of a conventional flow cytometer, imaging flow cytometry can eliminate erroneous results and increase accuracy in gating and analysis beyond what pure quantitative measurements from conventional flow cytometry can provide. Although imaging flow cytometry was used in our study, our results suggest that the signals indicating the presence of microclots should be easily detectable using a conventional flow cytometer. Flow cytometry is a more widely available technique than fluorescence microscopy and has been used in pathology laboratories for decades, rendering it a potentially more suitable and accessible method for detecting microclots in individuals suffering from Long COVID or conditions with similar pathology, such as myalgic encephalomyelitis. •Imaging flow cytometry utilizing a novel rapid flow cytometric detection method is a promising method for detecting amyloid fibrin(ogen) microclots in conditions associated with clotting pathology.•While this investigation represents a preliminary study, it lays the foundation for further research into the method's utility as a diagnostic tool for individuals with Long COVID.•Though challenging, future research can explore potential correlations between microclot detection and specific Long COVID symptoms and comorbidities, enhancing our understanding of the pathophysiology and tools to detect this condition.•The method's ability to evaluate amyloid microclot presence, concentration, and size offers valuable insights for clinical applications.</abstract><pub>Elsevier Ltd</pub><doi>10.1016/j.heliyon.2023.e19605</doi><orcidid>https://orcid.org/0000-0002-9108-2384</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2405-8440
ispartof Heliyon, 2023-09, Vol.9 (9), p.e19605-e19605, Article e19605
issn 2405-8440
2405-8440
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_038e1f97211846c48658f0f14aadf1d0
source ScienceDirect; Open Access: PubMed Central
subjects Amyloid microclots
Fluorescence
Imaging flow cytometry
Long COVID
title Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A00%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Accelerating%20discovery:%20A%20novel%20flow%20cytometric%20method%20for%20detecting%20fibrin(ogen)%20amyloid%20microclots%20using%20long%20COVID%20as%20a%20model&rft.jtitle=Heliyon&rft.au=Turner,%20Simone&rft.date=2023-09-01&rft.volume=9&rft.issue=9&rft.spage=e19605&rft.epage=e19605&rft.pages=e19605-e19605&rft.artnum=e19605&rft.issn=2405-8440&rft.eissn=2405-8440&rft_id=info:doi/10.1016/j.heliyon.2023.e19605&rft_dat=%3Cproquest_doaj_%3E2874837865%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c511t-57ebd429a1e09e9cea1180d53bbdeba0f1d4b90e6b927ddc2d850907200470bc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2874837865&rft_id=info:pmid/&rfr_iscdi=true